Overview

A Phase II Study of QL1706 With Anti-angiogenesis Therapy and Chemotherapy in Extensive-stage Small Cell Lung Cancer.

Status:
NOT_YET_RECRUITING

Trial end date:
2027-06-01

Target enrollment:

Participant gender:

Summary

This single-arm, open-label, Phase II study assesses first-line QL1706 + bevacizumab (anti-VEGF) + platinum/etoposide chemotherapy to treat nave ES-SCLC patients.The main questions it aims to answer are: Evaluate efficacy and safety of this quadruplet regimen in ES-SCLC Explore correlations between tumor biomarkers and treatment efficacy Participants will: Histologically or cytologically confirmed, treatment-nave extensive-stage small cell lung cancer (ES-SCLC). Willing to provide archived or fresh tumor tissue samples. If unavailable, enrollment may proceed per investigator assessment. At least one measurable lesion per RECIST v1.1

Phase:

PHASE2

Details

Lead Sponsor:

Zhijie Wang

Collaborators:

Hebei Medical University Fourth Hospital
Peking University Cancer Hospital & Institute
Peking University People's Hospital
Renmin Hospital of Wuhan University
Shanxi Province Cancer Hospital
Tianjin Medical University Cancer Institute and Hospital
Wuhan TongJi Hospital

Treatments:

Bevacizumab
Carboplatin
Cisplatin
Etoposide